Headquartered in Sunrise, FL Fiscal year ends December NYSE: MD pediatrix.com
Pediatrix Medical Group, Inc. (NYSE: MD), formerly known as Mednax, is a physician services company. Its affiliated clinicians care for women, babies and children across the continuum of care, in both hospital settings and office-based practices.
Specialties include obstetrics, maternal-fetal medicine and neonatology, along with multiple pediatric subspecialties. Neonatal intensive care unit (NICU) services are a core hospital-based offering. The company works through approximately 4,300 affiliated physicians and other clinicians.
Revenue comes mainly from net patient service revenue reimbursed by commercial and government payors such as Medicaid. It is supplemented by contract and administrative fees from hospital partners.
The company was founded in 1979 as a single neonatology practice. It has since undergone portfolio management and transformation initiatives, including practice dispositions, a transition to a hybrid revenue cycle management model, and a renewed focus on its hospital-based and maternal-fetal service lines. It also pursues selective acquisitions.
The company invests in research, education, quality improvement and safety initiatives. It actively returns capital through share repurchases. Updated
Buybacks are doing the heavy lifting at Pediatrix: $83 million repurchased in the quarter cut the diluted share count to 79.7 million, pushing adjusted EPS past expectations even as adjusted EBITDA slipped. Revenue came in just above expectations, and full-year EBITDA guidance of $290 million to $300 million was reiterated.
Pediatrix Medical Group, Inc. (NYSE: MD), formerly known as Mednax, is a physician services company. Its affiliated clinicians care for women, babies and children across the continuum of care, in both hospital settings and office-based practices.
The Wall Street consensus 12-month price target for MD is $29.17.